Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIPPI: HIPEC in Ovarian Cancer
NCT03842982Phase 3Active, not recruiting
- Sponsor
- Centre Oscar Lambret
- Start
- May 2019
- Primary completion
- Feb 2031
- Modality
- Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of Cisplatin micelle injection (HA132) in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Centre Oscar Lambret. Primary endpoint: Disease-free Survival at 5 years. Started May 2019; status: active, not recruiting.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03842982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03842982.